The global Radiopharmaceuticals in Nuclear Medicine market size was valued at USD 4943.7 million in 2023 and is forecast to a readjusted size of USD 6857.2 million by 2030 with a CAGR of 4.8% during review period.
Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases. Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report includes an overview of the development of the Radiopharmaceuticals in Nuclear Medicine industry chain, the market status of Diagnostic Application (Diagnostic Radiopharmaceuticals, Therapy Radiopharmaceuticals), Therapeutic Application (Diagnostic Radiopharmaceuticals, Therapy Radiopharmaceuticals), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Radiopharmaceuticals in Nuclear Medicine.
Regionally, the report analyzes the Radiopharmaceuticals in Nuclear Medicine markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Radiopharmaceuticals in Nuclear Medicine market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Radiopharmaceuticals in Nuclear Medicine market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Radiopharmaceuticals in Nuclear Medicine industry.
The report involves analyzing the market at a macro level:
麻豆原创 Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K MT), revenue generated, and market share of different by Type (e.g., Diagnostic Radiopharmaceuticals, Therapy Radiopharmaceuticals).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Radiopharmaceuticals in Nuclear Medicine market.
Regional Analysis: The report involves examining the Radiopharmaceuticals in Nuclear Medicine market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
麻豆原创 Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Radiopharmaceuticals in Nuclear Medicine market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Radiopharmaceuticals in Nuclear Medicine:
Company Analysis: Report covers individual Radiopharmaceuticals in Nuclear Medicine manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Radiopharmaceuticals in Nuclear Medicine This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Diagnostic Application, Therapeutic Application).
Technology Analysis: Report covers specific technologies relevant to Radiopharmaceuticals in Nuclear Medicine. It assesses the current state, advancements, and potential future developments in Radiopharmaceuticals in Nuclear Medicine areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Radiopharmaceuticals in Nuclear Medicine market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
麻豆原创 Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
麻豆原创 Segmentation
Radiopharmaceuticals in Nuclear Medicine market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
麻豆原创 segment by Type
Diagnostic Radiopharmaceuticals
Therapy Radiopharmaceuticals
Enriched Stable Isotopes
麻豆原创 segment by Application
Diagnostic Application
Therapeutic Application
Research
Pharmaceutical
Other
Major players covered
Bracco Imaging S.P.A.
Cambridge Isotope Laboratories, Inc.
Cardinal Health, Inc.
Covidien, Plc
Eczacibasi-Monrol
Fujifilm Holdings Corporation
GE Healthcare (Subsidiary Of General Electric Company)
IBA Group
Isotec, Inc. (Sigma-Aldrich)
Lantheus Medical Imaging, Inc.
Nordion, Inc.
Ntp Radioisotopes (Pty), Ltd.
Siemens Healthcare (Subsidiary Of Siemens AG)
Taiyo Nippon Sanso Corporation
Urenco Limited
Rotem Industries, Ltd., Inc.
Australian Nuclear Association And Technology Organization (ANSTO)
Board of Radiation And Isotope Technology (BRIT)
Institute of Atomic Energy Polatom Radioisotope Centre
Institute of Isotopes Co., Ltd.
Institute Of Radioelement (IRE)
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Radiopharmaceuticals in Nuclear Medicine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Radiopharmaceuticals in Nuclear Medicine, with price, sales, revenue and global market share of Radiopharmaceuticals in Nuclear Medicine from 2019 to 2024.
Chapter 3, the Radiopharmaceuticals in Nuclear Medicine competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Radiopharmaceuticals in Nuclear Medicine breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Radiopharmaceuticals in Nuclear Medicine market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Radiopharmaceuticals in Nuclear Medicine.
Chapter 14 and 15, to describe Radiopharmaceuticals in Nuclear Medicine sales channel, distributors, customers, research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope of Radiopharmaceuticals in Nuclear Medicine
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global Radiopharmaceuticals in Nuclear Medicine Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Diagnostic Radiopharmaceuticals
1.3.3 Therapy Radiopharmaceuticals
1.3.4 Enriched Stable Isotopes
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global Radiopharmaceuticals in Nuclear Medicine Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Diagnostic Application
1.4.3 Therapeutic Application
1.4.4 Research
1.4.5 Pharmaceutical
1.4.6 Other
1.5 Global Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Size & Forecast
1.5.1 Global Radiopharmaceuticals in Nuclear Medicine Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Quantity (2019-2030)
1.5.3 Global Radiopharmaceuticals in Nuclear Medicine Average Price (2019-2030)
2 Manufacturers Profiles
2.1 Bracco Imaging S.P.A.
2.1.1 Bracco Imaging S.P.A. Details
2.1.2 Bracco Imaging S.P.A. Major Business
2.1.3 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Product and Services
2.1.4 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 Bracco Imaging S.P.A. Recent Developments/Updates
2.2 Cambridge Isotope Laboratories, Inc.
2.2.1 Cambridge Isotope Laboratories, Inc. Details
2.2.2 Cambridge Isotope Laboratories, Inc. Major Business
2.2.3 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Product and Services
2.2.4 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 Cambridge Isotope Laboratories, Inc. Recent Developments/Updates
2.3 Cardinal Health, Inc.
2.3.1 Cardinal Health, Inc. Details
2.3.2 Cardinal Health, Inc. Major Business
2.3.3 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Product and Services
2.3.4 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 Cardinal Health, Inc. Recent Developments/Updates
2.4 Covidien, Plc
2.4.1 Covidien, Plc Details
2.4.2 Covidien, Plc Major Business
2.4.3 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Product and Services
2.4.4 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 Covidien, Plc Recent Developments/Updates
2.5 Eczacibasi-Monrol
2.5.1 Eczacibasi-Monrol Details
2.5.2 Eczacibasi-Monrol Major Business
2.5.3 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Product and Services
2.5.4 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 Eczacibasi-Monrol Recent Developments/Updates
2.6 Fujifilm Holdings Corporation
2.6.1 Fujifilm Holdings Corporation Details
2.6.2 Fujifilm Holdings Corporation Major Business
2.6.3 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Product and Services
2.6.4 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 Fujifilm Holdings Corporation Recent Developments/Updates
2.7 GE Healthcare (Subsidiary Of General Electric Company)
2.7.1 GE Healthcare (Subsidiary Of General Electric Company) Details
2.7.2 GE Healthcare (Subsidiary Of General Electric Company) Major Business
2.7.3 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Product and Services
2.7.4 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 GE Healthcare (Subsidiary Of General Electric Company) Recent Developments/Updates
2.8 IBA Group
2.8.1 IBA Group Details
2.8.2 IBA Group Major Business
2.8.3 IBA Group Radiopharmaceuticals in Nuclear Medicine Product and Services
2.8.4 IBA Group Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.8.5 IBA Group Recent Developments/Updates
2.9 Isotec, Inc. (Sigma-Aldrich)
2.9.1 Isotec, Inc. (Sigma-Aldrich) Details
2.9.2 Isotec, Inc. (Sigma-Aldrich) Major Business
2.9.3 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Product and Services
2.9.4 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.9.5 Isotec, Inc. (Sigma-Aldrich) Recent Developments/Updates
2.10 Lantheus Medical Imaging, Inc.
2.10.1 Lantheus Medical Imaging, Inc. Details
2.10.2 Lantheus Medical Imaging, Inc. Major Business
2.10.3 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Product and Services
2.10.4 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.10.5 Lantheus Medical Imaging, Inc. Recent Developments/Updates
2.11 Nordion, Inc.
2.11.1 Nordion, Inc. Details
2.11.2 Nordion, Inc. Major Business
2.11.3 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Product and Services
2.11.4 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.11.5 Nordion, Inc. Recent Developments/Updates
2.12 Ntp Radioisotopes (Pty), Ltd.
2.12.1 Ntp Radioisotopes (Pty), Ltd. Details
2.12.2 Ntp Radioisotopes (Pty), Ltd. Major Business
2.12.3 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Product and Services
2.12.4 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.12.5 Ntp Radioisotopes (Pty), Ltd. Recent Developments/Updates
2.13 Siemens Healthcare (Subsidiary Of Siemens AG)
2.13.1 Siemens Healthcare (Subsidiary Of Siemens AG) Details
2.13.2 Siemens Healthcare (Subsidiary Of Siemens AG) Major Business
2.13.3 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Product and Services
2.13.4 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.13.5 Siemens Healthcare (Subsidiary Of Siemens AG) Recent Developments/Updates
2.14 Taiyo Nippon Sanso Corporation
2.14.1 Taiyo Nippon Sanso Corporation Details
2.14.2 Taiyo Nippon Sanso Corporation Major Business
2.14.3 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Product and Services
2.14.4 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.14.5 Taiyo Nippon Sanso Corporation Recent Developments/Updates
2.15 Urenco Limited
2.15.1 Urenco Limited Details
2.15.2 Urenco Limited Major Business
2.15.3 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Product and Services
2.15.4 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.15.5 Urenco Limited Recent Developments/Updates
2.16 Rotem Industries, Ltd., Inc.
2.16.1 Rotem Industries, Ltd., Inc. Details
2.16.2 Rotem Industries, Ltd., Inc. Major Business
2.16.3 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Product and Services
2.16.4 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.16.5 Rotem Industries, Ltd., Inc. Recent Developments/Updates
2.17 Australian Nuclear Association And Technology Organization (ANSTO)
2.17.1 Australian Nuclear Association And Technology Organization (ANSTO) Details
2.17.2 Australian Nuclear Association And Technology Organization (ANSTO) Major Business
2.17.3 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Product and Services
2.17.4 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.17.5 Australian Nuclear Association And Technology Organization (ANSTO) Recent Developments/Updates
2.18 Board of Radiation And Isotope Technology (BRIT)
2.18.1 Board of Radiation And Isotope Technology (BRIT) Details
2.18.2 Board of Radiation And Isotope Technology (BRIT) Major Business
2.18.3 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Product and Services
2.18.4 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.18.5 Board of Radiation And Isotope Technology (BRIT) Recent Developments/Updates
2.19 Institute of Atomic Energy Polatom Radioisotope Centre
2.19.1 Institute of Atomic Energy Polatom Radioisotope Centre Details
2.19.2 Institute of Atomic Energy Polatom Radioisotope Centre Major Business
2.19.3 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Product and Services
2.19.4 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.19.5 Institute of Atomic Energy Polatom Radioisotope Centre Recent Developments/Updates
2.20 Institute of Isotopes Co., Ltd.
2.20.1 Institute of Isotopes Co., Ltd. Details
2.20.2 Institute of Isotopes Co., Ltd. Major Business
2.20.3 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Product and Services
2.20.4 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.20.5 Institute of Isotopes Co., Ltd. Recent Developments/Updates
2.21 Institute Of Radioelement (IRE)
2.21.1 Institute Of Radioelement (IRE) Details
2.21.2 Institute Of Radioelement (IRE) Major Business
2.21.3 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Product and Services
2.21.4 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.21.5 Institute Of Radioelement (IRE) Recent Developments/Updates
3 Competitive Environment: Radiopharmaceuticals in Nuclear Medicine by Manufacturer
3.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Manufacturer (2019-2024)
3.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Manufacturer (2019-2024)
3.3 Global Radiopharmaceuticals in Nuclear Medicine Average Price by Manufacturer (2019-2024)
3.4 麻豆原创 Share Analysis (2023)
3.4.1 Producer Shipments of Radiopharmaceuticals in Nuclear Medicine by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2023
3.4.2 Top 3 Radiopharmaceuticals in Nuclear Medicine Manufacturer 麻豆原创 Share in 2023
3.4.2 Top 6 Radiopharmaceuticals in Nuclear Medicine Manufacturer 麻豆原创 Share in 2023
3.5 Radiopharmaceuticals in Nuclear Medicine 麻豆原创: Overall Company Footprint Analysis
3.5.1 Radiopharmaceuticals in Nuclear Medicine 麻豆原创: Region Footprint
3.5.2 Radiopharmaceuticals in Nuclear Medicine 麻豆原创: Company Product Type Footprint
3.5.3 Radiopharmaceuticals in Nuclear Medicine 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Size by Region
4.1.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Region (2019-2030)
4.1.2 Global Radiopharmaceuticals in Nuclear Medicine Consumption Value by Region (2019-2030)
4.1.3 Global Radiopharmaceuticals in Nuclear Medicine Average Price by Region (2019-2030)
4.2 North America Radiopharmaceuticals in Nuclear Medicine Consumption Value (2019-2030)
4.3 Europe Radiopharmaceuticals in Nuclear Medicine Consumption Value (2019-2030)
4.4 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Consumption Value (2019-2030)
4.5 South America Radiopharmaceuticals in Nuclear Medicine Consumption Value (2019-2030)
4.6 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Consumption Value (2019-2030)
5 麻豆原创 Segment by Type
5.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Type (2019-2030)
5.2 Global Radiopharmaceuticals in Nuclear Medicine Consumption Value by Type (2019-2030)
5.3 Global Radiopharmaceuticals in Nuclear Medicine Average Price by Type (2019-2030)
6 麻豆原创 Segment by Application
6.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Application (2019-2030)
6.2 Global Radiopharmaceuticals in Nuclear Medicine Consumption Value by Application (2019-2030)
6.3 Global Radiopharmaceuticals in Nuclear Medicine Average Price by Application (2019-2030)
7 North America
7.1 North America Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Type (2019-2030)
7.2 North America Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Application (2019-2030)
7.3 North America Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Size by Country
7.3.1 North America Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Country (2019-2030)
7.3.2 North America Radiopharmaceuticals in Nuclear Medicine Consumption Value by Country (2019-2030)
7.3.3 United States 麻豆原创 Size and Forecast (2019-2030)
7.3.4 Canada 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Mexico 麻豆原创 Size and Forecast (2019-2030)
8 Europe
8.1 Europe Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Type (2019-2030)
8.2 Europe Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Application (2019-2030)
8.3 Europe Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Size by Country
8.3.1 Europe Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Country (2019-2030)
8.3.2 Europe Radiopharmaceuticals in Nuclear Medicine Consumption Value by Country (2019-2030)
8.3.3 Germany 麻豆原创 Size and Forecast (2019-2030)
8.3.4 France 麻豆原创 Size and Forecast (2019-2030)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Russia 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Italy 麻豆原创 Size and Forecast (2019-2030)
9 Asia-Pacific
9.1 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Size by Region
9.3.1 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Consumption Value by Region (2019-2030)
9.3.3 China 麻豆原创 Size and Forecast (2019-2030)
9.3.4 Japan 麻豆原创 Size and Forecast (2019-2030)
9.3.5 Korea 麻豆原创 Size and Forecast (2019-2030)
9.3.6 India 麻豆原创 Size and Forecast (2019-2030)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2019-2030)
9.3.8 Australia 麻豆原创 Size and Forecast (2019-2030)
10 South America
10.1 South America Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Type (2019-2030)
10.2 South America Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Application (2019-2030)
10.3 South America Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Size by Country
10.3.1 South America Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Country (2019-2030)
10.3.2 South America Radiopharmaceuticals in Nuclear Medicine Consumption Value by Country (2019-2030)
10.3.3 Brazil 麻豆原创 Size and Forecast (2019-2030)
10.3.4 Argentina 麻豆原创 Size and Forecast (2019-2030)
11 Middle East & Africa
11.1 Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Size by Country
11.3.1 Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Consumption Value by Country (2019-2030)
11.3.3 Turkey 麻豆原创 Size and Forecast (2019-2030)
11.3.4 Egypt 麻豆原创 Size and Forecast (2019-2030)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2019-2030)
11.3.6 South Africa 麻豆原创 Size and Forecast (2019-2030)
12 麻豆原创 Dynamics
12.1 Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Drivers
12.2 Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Restraints
12.3 Radiopharmaceuticals in Nuclear Medicine Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Radiopharmaceuticals in Nuclear Medicine and Key Manufacturers
13.2 Manufacturing Costs Percentage of Radiopharmaceuticals in Nuclear Medicine
13.3 Radiopharmaceuticals in Nuclear Medicine Production Process
13.4 Radiopharmaceuticals in Nuclear Medicine Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Radiopharmaceuticals in Nuclear Medicine Typical Distributors
14.3 Radiopharmaceuticals in Nuclear Medicine Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Bracco Imaging S.P.A.
Cambridge Isotope Laboratories, Inc.
Cardinal Health, Inc.
Covidien, Plc
Eczacibasi-Monrol
Fujifilm Holdings Corporation
GE Healthcare (Subsidiary Of General Electric Company)
IBA Group
Isotec, Inc. (Sigma-Aldrich)
Lantheus Medical Imaging, Inc.
Nordion, Inc.
Ntp Radioisotopes (Pty), Ltd.
Siemens Healthcare (Subsidiary Of Siemens AG)
Taiyo Nippon Sanso Corporation
Urenco Limited
Rotem Industries, Ltd., Inc.
Australian Nuclear Association And Technology Organization (ANSTO)
Board of Radiation And Isotope Technology (BRIT)
Institute of Atomic Energy Polatom Radioisotope Centre
Institute of Isotopes Co., Ltd.
Institute Of Radioelement (IRE)
听
听
*If Applicable.
